PDS Biotechnology Corp
EU6
Company Profile
Business description
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Contact
303A College Road
East PrincetonNJ08540
USAT: +1 800 208-3343
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
24
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
A new report from Morningstar shows opportunities for income investors.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
With outstanding long-term estimates, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,686.30 | 8.30 | -0.10% |
| CAC 40 | 7,989.44 | 8.37 | 0.10% |
| DAX 40 | 23,091.87 | 186.98 | -0.80% |
| Dow JONES (US) | 46,245.41 | 493.15 | 1.08% |
| FTSE 100 | 9,531.01 | 3.36 | 0.04% |
| HKSE | 25,220.02 | 615.55 | -2.38% |
| NASDAQ | 22,273.08 | 195.03 | 0.88% |
| Nikkei 225 | 48,625.88 | 1,198.06 | -2.40% |
| NZX 50 Index | 13,419.40 | 20.00 | -0.15% |
| S&P 500 | 6,602.99 | 64.23 | 0.98% |
| S&P/ASX 200 | 8,416.50 | 0.00 | 0.00% |
| SSE Composite Index | 3,834.89 | 96.16 | -2.45% |